Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at mmm-online.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

The FDA issued an Untitled Letter to Travere Therapeutics concerning the visual aid used in marketing Filspari, a kidney disease drug, indicating regulatory concerns with promotional materials.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

FDA scrutiny on your marketing materials for kidney drugs just tightened. If you promote renal therapies, now is the time to review your visual aids and avoid possible enforcement.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDAuntitled-letterregulatorypharma-marketingkidney-disease